8-K current report · filed Oct 28, 2026

Arcutis Biotherapeutics, Inc. (ARQT) 8-K Current Report: October 28, 2026

Item 5.02Item EX-99.1Item 7.01ARQT overview

Short answer

Arcutis Biotherapeutics, Inc. (ARQT) filed an 8-K current report with the SEC on October 28, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Board expanded from 10 to 11 directors, adding independent Class II director Robert Scott through the 2028 annual meeting.

Arcutis Biotherapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Board expanded from 10 to 11 directors, adding independent Class II director Robert Scott through the 2028 annual meeting
  • Scott brings former AbbVie Chief Medical Officer and Amgen global development leadership experience, strengthening pharmaceutical development oversight
  • Initial option award covers 20,507 shares, vesting in three equal annual installments
  • Prorated annual equity award fair valued at approximately $350,000, plus $50,000 board and $5,000 committee cash retainers
  • No disclosed related-party transactions, family relationships, or selection arrangements reducing governance concerns

Item 7.01 · Regulation FD Disclosure

  • Arcutis appointed Dr. Scott, a leadership change potentially affecting strategy and execution
  • Press release dated October 28, 2026, contains the appointment details and should be reviewed for role and transition terms

Item EX-99.1 · Exhibit EX-99.1

  • Rob Scott, MD appointed to Arcutis’ board effective October 23, 2026
  • Former AbbVie chief medical officer brings experience across approximately 40 new molecular entities and 14 major approvals
  • Appointment strengthens oversight of ZORYVE expansion and Arcutis’ novel biologic pipeline
  • Scott’s background in dermatology, immunology, clinical development, and regulatory strategy supports pipeline execution
  • No compensation terms or committee assignments disclosed in the release

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Arcutis Biotherapeutics, Inc. 8-K filings

Get the next ARQT 8-K as it lands

Follow ARQT for push alerts, or ask the research agent what this filing means.